logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Purdue Pharma LP drugs

    FiltersReset Filters
    3 results

    • butrans

      (buprenorphine)
      Purdue Pharma LP
      Usage: BUTRANS is indicated for managing severe, persistent pain requiring long-term opioid therapy when alternative treatments are inadequate. It should be used cautiously due to risks of addiction and overdose, and is not intended for as-needed pain relief.

    • hysingla er

      (hydrocodone bitartrate)
      Purdue Pharma LP
      Usage: HYSINGLA ER is indicated for managing severe, persistent pain requiring long-term opioid treatment when other options are insufficient. It should be reserved for patients unsuitable for non-opioid analgesics or immediate-release opioids due to risks of addiction, abuse, and overdose. It is not for as-needed use.

    • oxycontin

      (oxycodone hydrochloride)
      Purdue Pharma LP
      Usage: OXYCONTIN is indicated for managing severe, persistent pain in adults and opioid-tolerant pediatric patients (11+ years) requiring long-term opioid treatment when alternatives are inadequate. It is not for as-needed use and carries risks of addiction, abuse, and overdose.